NASDAQ:MLTX MoonLake Immunotherapeutics (MLTX) Stock Price, News & Analysis $44.77 -0.14 (-0.31%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$44.48▼$45.7250-Day Range$38.43▼$50.1952-Week Range$35.11▼$64.98Volume84,491 shsAverage Volume409,745 shsMarket Capitalization$2.86 billionP/E RatioN/ADividend YieldN/APrice Target$79.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get MoonLake Immunotherapeutics alerts: Email Address MoonLake Immunotherapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.77 Rating ScoreUpside/Downside76.5% Upside$79.00 Price TargetShort InterestBearish15.09% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.08Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.21) to ($1.95) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.26 out of 5 starsMedical Sector787th out of 936 stocksPharmaceutical Preparations Industry366th out of 436 stocks 3.4 Analyst's Opinion Consensus RatingMoonLake Immunotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.77, and is based on 10 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageMoonLake Immunotherapeutics has only been the subject of 3 research reports in the past 90 days.Read more about MoonLake Immunotherapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted15.09% of the float of MoonLake Immunotherapeutics has been sold short.Short Interest Ratio / Days to CoverMoonLake Immunotherapeutics has a short interest ratio ("days to cover") of 22.6, which indicates bearish sentiment.Change versus previous monthShort interest in MoonLake Immunotherapeutics has recently increased by 1.02%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldMoonLake Immunotherapeutics does not currently pay a dividend.Dividend GrowthMoonLake Immunotherapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MLTX. Previous Next 2.8 News and Social Media Coverage News SentimentMoonLake Immunotherapeutics has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for MoonLake Immunotherapeutics this week, compared to 3 articles on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MoonLake Immunotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.02% of the stock of MoonLake Immunotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions93.85% of the stock of MoonLake Immunotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about MoonLake Immunotherapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for MoonLake Immunotherapeutics are expected to decrease in the coming year, from ($1.21) to ($1.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MoonLake Immunotherapeutics is -59.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MoonLake Immunotherapeutics is -59.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMoonLake Immunotherapeutics has a P/B Ratio of 5.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about MoonLake Immunotherapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agency5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here.Click here to pay just $5 for a full year of Stealth Trades About MoonLake Immunotherapeutics Stock (NASDAQ:MLTX)MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.Read More MLTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MLTX Stock News HeadlinesJuly 21, 2024 | americanbankingnews.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Given Consensus Rating of "Moderate Buy" by BrokeragesJuly 18, 2024 | seekingalpha.comMoonLake Immunotherapeutics: Second Late-Stage Program Moves Sonelokimab ForwardJuly 26, 2024 | Traders Agency (Ad)5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here.May 17, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for MoonLake Immunotherapeutics Amidst Promising Clinical Trials and Strategic Development PlansMay 16, 2024 | globenewswire.comMoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativaMay 12, 2024 | seekingalpha.comMoonLake Immunotherapeutics' Competitive Edge In Autoimmune Market ExpansionMay 10, 2024 | markets.businessinsider.comMoonLake Immunotherapeutics Buy Rating Justified by Strong Clinical Execution and Financial PositionMay 8, 2024 | markets.businessinsider.comMoonLake Immunotherapeutics Earns Buy Rating: Advancing Clinical Programs and Strong Financial PositionJuly 26, 2024 | DTI (Ad)How a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…May 8, 2024 | markets.businessinsider.comMoonLake Immunotherapeutics’ Strong Buy Rating: Promising Clinical Developments and Significant Market PotentialMay 8, 2024 | finance.yahoo.comMoonLake Immunotherapeutics Reports Q1 2024 Financial OutcomesMay 7, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX) and Curis (CRIS)May 7, 2024 | finance.yahoo.comMoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business UpdateApril 26, 2024 | markets.businessinsider.comStrong Buy Rating for MoonLake Immunotherapeutics Based on Promising Sonelokimab Clinical Trials and Market PotentialApril 23, 2024 | markets.businessinsider.comMoonLake Immunotherapeutics: A Promising Outlook with Sonelokimab’s Potential in the HS MarketApril 23, 2024 | markets.businessinsider.comBuy Rating Affirmed for MoonLake Immunotherapeutics Amid Promising Clinical Results for SonelokimabApril 11, 2024 | markets.businessinsider.comMoonLake Immunotherapeutics Buy Rating: Strategic Partnerships and Market Potential Fuel OptimismApril 10, 2024 | businesswire.comMoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint ConditionsSee More Headlines Receive MLTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MoonLake Immunotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/12/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MLTX CUSIPN/A CIK1821586 Webwww.moonlaketx.com Phone41-41-510-8022FaxN/AEmployees2Year FoundedN/APrice Target and Rating Average Stock Price Target$79.00 High Stock Price Target$104.00 Low Stock Price Target$59.00 Potential Upside/Downside+76.9%Consensus RatingModerate Buy Rating Score (0-4)2.77 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($0.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,010,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-7.92% Return on Assets-7.76% Debt Debt-to-Equity RatioN/A Current Ratio62.12 Quick Ratio62.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.15 per share Price / Book5.48Miscellaneous Outstanding Shares63,890,000Free Float56,208,000Market Cap$2.85 billion OptionableOptionable Beta1.25 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Jorge Santos da Silva (Age 46)Co-Founder, CEO & Director Comp: $1.11MDr. Kristian Reich (Age 58)Co-Founder & Chief Scientific Officer Comp: $1.2MMr. Matthias Bodenstedt (Age 36)Chief Financial Officer Comp: $588.25kMr. Oliver DaltropChief Technical OfficerNicolas MosimannGeneral CounselLuciana MarquesDirector of HR, People & CultureMs. Nuala BrennanChief Clinical Development OfficerMore ExecutivesKey CompetitorsCipher MiningNASDAQ:CIFRDocGoNASDAQ:DCGOEdtechX Holdings Acquisition Corp. IINASDAQ:EDTXQuantum-SiNASDAQ:QSIPTK AcquisitionNYSE:PTKView All CompetitorsInsiders & InstitutionsHarbor Capital Advisors Inc.Bought 30,481 shares on 7/9/2024Ownership: 0.061%DNB Asset Management ASBought 1,694 shares on 7/5/2024Ownership: 0.012%Ikarian Capital LLCSold 42,600 shares on 5/17/2024Ownership: 0.000%Kennedy Capital Management LLCSold 8,622 shares on 5/16/2024Ownership: 0.042%California State Teachers Retirement SystemBought 429 shares on 5/16/2024Ownership: 0.026%View All Insider TransactionsView All Institutional Transactions MLTX Stock Analysis - Frequently Asked Questions How have MLTX shares performed this year? MoonLake Immunotherapeutics' stock was trading at $60.39 on January 1st, 2024. Since then, MLTX shares have decreased by 25.9% and is now trading at $44.77. View the best growth stocks for 2024 here. How were MoonLake Immunotherapeutics' earnings last quarter? MoonLake Immunotherapeutics (NASDAQ:MLTX) posted its quarterly earnings data on Sunday, May, 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.03. Who are MoonLake Immunotherapeutics' major shareholders? MoonLake Immunotherapeutics' top institutional shareholders include Harbor Capital Advisors Inc. (0.06%) and DNB Asset Management AS (0.01%). Insiders that own company stock include Bihua Chen, Da Silva Jorge Santos, Matthias Bodenstedt and Kristian Reich. View institutional ownership trends. How do I buy shares of MoonLake Immunotherapeutics? Shares of MLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MLTX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MoonLake Immunotherapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share MoonLake Immunotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MLTX Stock Alerts